Objective: The objective of this study was to use a well-established monkey model of atherosclerosis to determine how life stage and preexisting atherosclerosis influence the effectiveness of high-isoflavone soy diet in inhibiting progression of atherosclerosis.
M orbidity and mortality rates attributable to cardiovascular disease among women are lower in Asian countries than in Western countries. It has been proposed that consumption of diets high in soy proteinVcharacteristic of traditional foods in Japan and ChinaVmay contribute to such cardioprotection. 1, 2 In addition, epidemiological studies have demonstrated that Asian women migrating to a Western country develop a cardiovascular disease burden similar to that of Western women, perhaps owing to changes in diet, including increased consumption of animal protein and decreased consumption of soy/ soy isoflavones. 3, 4 Isolated soy protein differs from animal protein in relation to peptides, proteins, overall amino acid composition, elevated isoflavone content, and other constituents, each of which may have biologic effects in vivo. The atheroprotective effects of dietary soy seem to be only minimally attributable to effects on plasma lipids, 5 and evidence from studies of isoflavone-rich soy versus isoflavone-poor soy (alcohol extract) indicated that soy isoflavones have atheroprotective effects. 5 However, no study has described the atherosclerosis burden of women who consume soy premenopausally and continue to do so postmenopausally in comparison with women who may have consumed animal protein during premenopause and then were supplemented with soy postmenopausally. Results from the Women's Isoflavone Soy Health (WISH) randomized clinical trial on the effects of soy supplementation on the progression of subclinical atherosclerosis (carotid artery intima-media thickness) in postmenopausal women aged 45 to 92 years 6 suggested that soy supplementation did not significantly reduce atherosclerosis progression across all individuals but was effective in a subset of women who had been postmenopausal for less than 5 years. In addition, a small group of Asian women treated with soy had a borderline significant reduction of atherosclerosis progression.
There are several unanswered questions concerning the effects of life stage on the cardiovascular effects of soy supplementation. In the present study, we attempted to model those questions by evaluating the progression of atherosclerosis in premenopausal and surgically postmenopausal cynomolgus monkeys fed a moderately atherogenic diet that derives most of its protein from either soy or casein-lactalbumin (CL) mixture. Specifically, we addressed the following questions: (1) To what extent does life stage/menopause status influence the atheroprotective effects of dietary soy? (2) What are the effects of consuming soy premenopausally and changing to a more Western diet (animal protein) postmenopausally on atherosclerosis progression? (3) Does postmenopausal soy supplementation provide atheroprotective effects on women who consumed a Western diet (animal protein) premenopausally?
METHODS

Monkeys, diets, and study design
One hundred adult female cynomolgus macaques (Macaca fascicularis) were imported from Indonesia (Institut Pertanian Bogor). Ninety-five monkeys began the study and were randomized to eat either an atherogenic control diet containing proteins derived from CL (CL, n = 43) or an atherogenic diet containing soy protein isolate (Soy, n = 42) as the primary source of protein for 34 months. Details about the animals and diets have been published previously. 7 Briefly, both diets were formulated to be identical in caloric contents of protein, fat, carbohydrate, and cholesterol (0.28 mg cholesterol/Cal) and to mimic a typical diet consumed by women in the United States. After 34 months of premenopausal diet, animals were ovariectomized and immediately randomized either to continue to be fed CL or soy or to be fed the other diet (CL or soy) for the subsequent 34 months (Fig. 1) . At the time of ovariectomy, a segment of the left common iliac artery (LCI) was removed surgically to determine the amount of atherosclerosis present at the end of the premenopausal phase (postmenopausal baseline [PBL] ). 7 The designations of the dietary regimens are as follows: a control group fed CL premenopausally and postmenopausally (CL-CL, n = 20); a group fed soy premenopausally and postmenopausally (Soy-Soy, n = 17); a group fed soy premenopausally and CL postmenopausally (Soy-CL, n = 17); and a group fed CL premenopausally and soy postmenopausally (CL-Soy, n = 17). The animals for subset analyses were fed CL-Soy and divided at the median of the premenopausal baseline plaque size. Only those monkeys that completed the study and from which we have complete data were considered eligible for the analysis.
All procedures involving animals were conducted in compliance with state and federal laws, standards of the US Department of Health and Human Services, and guidelines established by the Wake Forest University Animal Care and Use Committee.
FIG. 1.
Randomized monkey trial study design. CL diet (n = 37), CL proteinYbased atherogenic diet (0.28 mg cholesterol/Cal); Soy diet (n = 34), soy proteinYbased atherogenic diet (0.28 mg cholesterol/Cal; treatment diet). CL-CL (control group, n = 20), animals fed CL diet premenopausally and postmenopausally; Soy-Soy (n = 17), animals fed soy diet premenopausally and postmenopausally; Soy-CL (n = 17), animals fed soy diet premenopausally and switched to CL diet postmenopausally; CL-Soy (n = 17), animals fed CL diet premenopausally and switched to soy diet postmenopausally. CL, casein-lactalbumin.
Plasma lipid measurements
Concentrations of total plasma cholesterol (TPC), high-density lipoprotein cholesterol (HDL-c), very-low-density lipoprotein cholesterol (VLDL-c) plus low-density lipoprotein cholesterol (LDL-c), and triglycerides were determined at 10, 21, and 30 months after ovariectomy at the Comparative Medicine Research Center Clinical Chemistry Laboratory. The mean of three measurements is reported. Details about the methods used to evaluate plasma lipid and lipoprotein concentrations, as well as lipid profiles during the premenopausal period, have been published previously. 8 
Serum isoflavone measurements
During the postmenopausal period, monkeys were fed in the morning and sedated 4 hours after feeding for blood collection. Serum isoflavone concentrations were determined at 12 and 23 months postmenopause using liquid chromatographyYphotodiode array mass spectrometry. 9 Plasma concentrations during the premenopausal stage have been published previously. 7 
Measurements of plaque progression
To estimate changes from PBL in plaque size and severity for individual monkeys, we used the LCIVa paired artery previously shown to have essentially the same plaque sizes in both the left and the right arteries and to be highly associated with coronary artery plaque extent. 5, 10 Briefly, monkeys were anesthetized with an intramuscular injection of ketamine (10 mg/kg) followed by isoflurane gas. The LCI was approached by abdominal incision and blunt-dissected from the vein. After proximal and distal ligatures had been placed in the LCI, approximately 0.5-cm sections were excised from each animal. The artery sections were cleaned of adventitial tissue and opened longitudinally, and a portion was fixed in 4% paraformaldehyde and embedded in paraffin block. PBL atherosclerotic plaque size was determined in the LCI, which was removed at the time of ovariectomy using the methods described below. Atherosclerosis and gene expression outcomes from this baseline iliac artery have been previously published. 7 
Necropsy procedure
After 34 months of postmenopausal diet, monkeys were euthanized with sodium pentobarbital (100 mg/kg, IV), a method consistent with the recommendations of the American Veterinary Medical Association panel on euthanasia. The circulatory system was flushed with lactated Ringer solution. The heart was removed and perfusion-fixed for 1 hour at 100 mm Hg using 10% neutral buffered formalin. The right common iliac artery (RCI) (postmenopausal outcome) and coronary arteries were collected for further histopathologic evaluation. The RCI was opened longitudinally and laid flat on cardboard, and a portion was immersion-fixed in 10% neutral buffered formalin. Each coronary artery (left anterior descending artery, left circumflex artery, and right coronary artery) was sectioned in five blocks (3 mm each in length) and cut perpendicular to the long axis of the arteries. Fivemicrometer sections were made from each block and stained with VerhoeffYvan Gieson stain. Each section was captured digitally using a Nikon DS Fi1 camera mounted on an Olympus BH-2 microscope equipped with a mechanical stage. Morphometric measurements were made using Image-Pro Plus version 7.0 imaging software (Media Cybernetics Inc, Bethesda, MD).
Plaque extent and American Heart Association severity grades
Plaque extent was expressed as cross-sectional intimal area (in square millimeters). For the coronary arteries, the mean of the intimal areas of the 15 blocks (mean cross-sectional intimal area) was reported as previously described. 11 Because plaque complications occur independently of plaque extent, lesions were also scored for severity using the American Heart Association guidelines 12 : grade 0, arteries with no lesion; grade I, intimal lesions consisting of smooth muscle adaptive thickening; grade II, smooth muscle adaptive thickening containing macrophage foam cells; grade III, necrosis of macrophages and accumulation of small pools of extracellular lipid; grade IV, lesions in which small pools of extracellular lipid had coalesced into a core of extracellular lipid; grade V, the core of extracellular lipid was separated from the lumen by a definitive fibromuscular cap. Grades were determined by three independent observers who were blinded to treatment.
Statistical analyses General analyses
Measurements of the plaque extent of the LCI, RCI, and coronary arteries were square root transformed so that the distribution of each measure would closely conform to a normal distribution. Change in ($) plaque extent of common iliac arteries was calculated by subtracting the square-rooted RCI plaque extent [outcome] from the square-rooted LCI plaque extent [baseline] . Means of changes in values for each condition are presented as mean (SEM) on the original measurement scale based on backtransformation. One-way analysis of variance was used to compare changes in plaque extent of iliac arteries (in square millimeters) and coronary plaque extent (in square millimeters) of each condition to the control group (CL-CL group). Fisher's exact test was used to evaluate the frequency of American Heart Association grades (plaque severity), comparing each condition to control (CL-CL group) in relation to the distribution of minimally affected lesions (grades 0, I, and II) versus more severely affected lesions (grade III or higher). P values were adjusted for multiple comparisons using Bonferroni correction.
Subgroup analyses
The finding in the WISH trial that women who had been postmenopausal for less than 5 years experienced reduced rates of progression of carotid artery intima-media thickness suggested that their favorable outcome may have been attributable to the fact that their atherosclerosis was less extensive (plaques were smaller) when the soy supplement was administered. Consequently, we conducted subset analyses on monkeys fed CL diet premenopausally. Here, monkeys were divided at the median based on premenopausal plaque extent (PBL); in each such subgroup, coronary artery atherosclerosis extent and severity and change in common iliac atherosclerosis in monkeys fed CL diet were compared with those supplemented with soy diet postmenopausally. Outcome conditions were compared using t test. P G 0.05 was considered statistically significant. Both general and subgroup analyses were performed using SPSS 11.5 software (SPSS Inc, Chicago, IL).
RESULTS
Plasma lipid and lipoprotein concentrations
Mean plasma lipid and lipoprotein concentrations for the four groups during the postmenopausal period are presented in Table. For all variables, except for plasma triglycerides, beneficial effects (lowered TPC and LDL-c + VLDL-c and increased HDL-c) were observed under CL-Soy and Soy-Soy conditions compared with the CL-CL group. Soy-CL condition was not statistically different from CL-CL condition.
Serum isoflavone concentrations
Monkeys fed soy diet (CL-Soy and Soy-Soy conditions) had significantly elevated mean (SEM) serum concentrations of the two primary isoflavones genistein (CL-Soy, 167 [20] 
Postmenopausal iliac artery atherosclerosis progression for all monkeys in the trial
Postmenopausal atherosclerosis progression was determined as the difference in iliac artery plaque size from PBL to the end of the 34-month trail (ie, change in iliac artery atherosclerosis). (SEM) . P values represent group differences relative to CL-CL (control group). CL-CL (n = 20), animals fed CL diet premenopausally and postmenopausally; Soy-Soy (n = 17), animals fed soy diet premenopausally and postmenopausally; Soy-CL (n = 17), animals fed soy diet premenopausally and switched to CL diet postmenopausally; CL-Soy (n = 17), animals fed CL diet premenopausally and switched to soy diet postmenopausally. TPC, total plasma cholesterol; HDL-c, high-density lipoprotein cholesterol; VLDL-c, very-low-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; TG, triglycerides; CL, casein-lactalbumin. ), the difference was not statistically significant (P = 0.29).
FIG. 2. Change in common iliac
Coronary artery atherosclerosis extent and severity for all monkeys in the trial
The extent of coronary artery atherosclerosis under different treatment conditions is presented in Figure 3A 2 ). The effects of soy on plaque severity are presented in Figure 3B . Monkeys that consumed soy both premenopausally and postmenopausally (Soy-Soy) had a significantly lower proportion of complicated plaques (41.1%, 7/17) than the CL-CL group (90%, 18/20) (P = 0.004). Plaque severity scores of the CL-Soy and Soy-CL groups were not statistically different from scores in the CL-CL group. Figure 4 illustrates differences in the premenopausal and postmenopausal iliac artery atheroscleroses of monkeys that consumed CL premenopausally and were divided into subgroups based on having either small or large plaques at PBL. Among monkeys with small plaques at ovariectomy, soy markedly reduced plaque progression (mean [SEM] 
Subgroup analysis of iliac artery atherosclerosis progression
Subgroup analyses of coronary artery atherosclerosis extent and severity
The effect of CL-Soy diet treatment on coronary artery atherosclerosis in relation to premenopausal iliac artery plaque size is depicted in Figure 5A . Animals above and below the median in premenopausal plaque size differed substantially in coronary artery extent despite having the same premenopausal and postmenopausal diet treatment (CL-Soy, mean [ ). The effect of pretreatment iliac artery plaque size on the frequency of occurrence of complicated plaques is presented in Figure 5B . Soy diet significantly reduced the percentage of complicated coronary artery plaques among those monkeys with small pretreatment plaques, whereas no such beneficial effect was seen among those monkeys with small pretreatment plaques that continued to be fed CL. Notably, the occurrence of complicated plaques was the same for soy-and CL-fed monkeys with large plaques at PBL.
DISCUSSION
The results of our study addressed three critical questions: (1) To what extent is premenopausal and postmenopausal soy consumption atheroprotective? Answer: Coronary artery atherosclerosis extent and severity were significantly inhibited in monkeys fed soy both premenopausally and postmenopausally. (2) What are the effects on atherosclerosis progression of consuming soy premenopausally and changing to a more Western diet postmenopausally? Answer: Atherosclerosis progression in the iliac arteries and coronary artery atherosclerosis in animals initiating CL diet postmenopausally were not different from those consuming the CL diet premenopausally and postmenopausally. (3) Does postmenopausal soy supplementation provide atheroprotective effects on animals that consumed a Western diet premenopausally? Answer: Postmenopausal soy consumption inhibited atherosclerosis in both common iliac arteries and coronary arteries only in those monkeys with relatively small plaques at the start of the postmenopausal treatment phase (ie, those that were below the median).
Among other results, postmenopausal soy treatment, relative to CL exposure, had a robust beneficial effect on plasma lipid profiles. The favorable outcome on plasma lipid profiles was observed irrespective of the premenopausal diet. 8 The effects of soy intervention on the plasma lipid profiles in this study were larger than reported to occur when soy supplements are given to women. Several well-controlled studies have concluded that soy supplementation results in limited reductions in TPC concentrations (primarily in LDL-c fraction) and no changes in HDL-c concentrations.
13<15 That same result was noted in the WISH trial. 6 One potential explanation for the difference in responsiveness to soy between our monkey model and women is the amount of soy consumed, as more than 80% of protein in the soy diet was derived from soy. The amount (25 g/d) received by women would only account for about 54% or so of their daily protein requirement of 46 g/day (Centers for Disease Control and Prevention, http://www.cdc.gov/nutrition/everyone/basics/protein.html). Much attention has been focused on the fact that cynomolgus monkeys are efficient at converting daidzein into equol, whereas only a fraction (25%-40%) of women are significant equol producers. 16 However, we previously observed no effect of dietary equol on plasma lipids in ovariectomized monkeys, suggesting that the differing effects of soy on plasma lipids in women and monkeys are not dependent on equol. 17 Furthermore, we found no association between equol production among monkeys fed soy in the postmenopausal phase and any of the outcome measures. In addition, the WISH trial found that the effects of soy supplementation on carotid artery intima-media thickness were similar in equol producers and their nonconverting counterparts. 6 The WISH trial focused on the effects of dietary soy on carotid artery intima-media thickness. The current results extend the WISH trial by including measures of atherosclerosis extent in coronary arteries and at two time points in the iliac arteries, a surrogate measure that has been shown in prior studies to be highly correlated with coronary atherosclerosis extent. 8, 10, 18 The present study also controlled for soy protein exposure (in the context of an atherogenic diet that remained relatively high in saturated fat and cholesterol) under premenopausal and surgically postmenopausal conditions, allowing atherosclerosis progression under different soy regimens to be compared. The translational relevance of atherosclerosis in the four treatment conditions seems clear: (1) CL-CL (control) condition represents women who habitually consume a typical American diet for their entire lives; (2) Soy-Soy condition represents women who habitually consume a typical Asian diet across their life span; (3) CL-Soy condition represents women who begin consuming soy at menopause; and (4) Soy-CL condition potentially reflects the experience of women who migrate from an Asian diet to a typical American diet.
In view of the beneficial effects of postmenopausal soy diets on plasma lipid profiles in this trial, we did not expect that there would be no overall inhibition of iliac artery atherosclerosis progression, regardless of the premenopausal diet. Again, considering the overall analysis, only monkeys that received soy both premenopausally and postmenopausally had less extensive and severe coronary artery atherosclerosis.
Although the measures of iliac artery atherosclerosis at the beginning and end of the postmenopausal phase allow one to estimate changes in atherosclerosis across time, interpretation of the coronary outcome is limited by the absence of a direct measure of coronary atherosclerosis at surgical menopause. Considering all treatment conditions, the only significant effect on coronary arteries (in both extent and severity) was observed in those animals that consumed soy both premenopausally and postmenopausally (ie, perhaps comparable to Asian women who continue to consume a diet high in soy). It is noteworthy that the coronary outcome is discordant with the beneficial postmenopausal effect of soy on the lipids of monkeys under CL-Soy condition (marked increases in HDL-c and reductions in VLDL-c + LDL-c). The lack of benefit of postmenopausal soy on lesion size could be explained by a previous finding that atherosclerotic lesion size does not necessarily decrease in response to lowering of plasma lipid, 19 although changes in lesion lipid and connective tissue content can occur. 20 We determined whether there was a subset of surgically postmenopausal monkeys that derived cardiovascular benefits from consuming the soy diet. As indicated, we conducted a subgroup analysis that focused only on animals thatVlike many American womenVconsumed CL diet premenopausally. Among those individuals, postmenopausal soy treatment significantly inhibited the progression of both iliac artery atherosclerosis and coronary artery atherosclerosis, but only in animals that started with relatively small lesions (below the median, as indicated by iliac artery atherosclerosis determined at surgical menopause). The results of our subgroup analyses suggest clearly that the stage of plaque progression premenopausally is a major determinant of the potential cardiovascular benefits of postmenopausal soy supplementationVa situation that may be comparable to the loss of beneficial effects from estradiol when plaques have progressed to the complicated stage. We have described in great detail this relative loss of the beneficial effects of estradiol in the presence of established lesions, 21 which is now commonly referred to as the Btiming hypothesis[. Interestingly, Hodis et al 6 speculated recently that the timing hypothesis may relate to phytoestrogens (isoflavones) in the same way as the estradiol effect (loss of estrogen receptors with plaque progression). Relative to the finding of an atheroprotective effect of soy diets fed to premenopausal monkeys, Walker et al 7 observed that arterial estrogen receptor-> expression was correlated with serum genistein concentrations (r = 0.45, P = 0.005) and that estrogen receptor-A was correlated with serum concentrations of daidzein (r = 0.39, P = 0.015). Their study suggested that the premenopausal atheroprotective effects of soy may relate to interactions occurring between isoflavones, estrogen receptors, and nuclear factor-JB. The lack of effect of soy diets on monkeys with relatively large (above the median) plaques may probably be related to the loss of arterial estrogen receptors, as estrogen receptor protein expression has been found to be reduced in atherosclerotic human arteries, negatively correlated with atherosclerosis in postmenopausal women, 22 and, most importantly, inversely associated with plaque size in both male and female monkeys. 7, 8 Postmenopausal serum isoflavones were not associated with atherosclerosis. It is important to point out some aspects of the isoflavone measures. Serum concentrations of the isoflavones were measured in blood samples collected 4 hours after feeding at two time points during the menopausal phase. We do not therefore have total exposure or area under the curve of isoflavone exposure with which to perform these analyses. We also do not have data on tissue levels of isoflavones, which could differ significantly from blood levels and play a role in biologic effects. Lastly, the proteins and peptides in soy also have bioactivity and could have atheroprotective effects. 23 More research needs to be performed to address these possibilities.
